CCO Treatment Updates
Changing the Outcome of CLL: Prognostic Tools and Novel Therapeutic Modalities
Diagnostic and Post-treatment Detection Factors |
Module 1 of 2 |
 
- John C. Byrd, MD
- Peter Hillmen, MB ChB, FRCP, FRCPath, PhD
|
|
|
Topics covered include:
- Introduction
- p53 Mutations in Patients With CLL
- Immunoglobulin Heavy Chain Variable Region [IgVH]] Mutation Status and Surrogates
- Predictors of Response to Treatment in Patients With CLL
- IgVH Mutation Status in Patients With CLL and Response to Treatment
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe current and novel prognostic markers in CLL Discuss the implications for response evaluation by National Cancer Institute (NCI) criteria and polymerase chain reaction (PCR)- or flow cytometry-measured minimal residual disease Review markers that aid in the prediction of treatment response
|
Treatment Issues in CLL |
Module 2 of 2 |
|
Program Director: John C. Byrd, MD
  
- Andreas Engert, MD
- Susan M. O'Brien, MD
- Parameswaran Venugopal, MD
|
|
|
Topics covered include:
- Introduction-Treatment of Patients With CLL
- Rituximab's Role in CLL
- Rituximab in Combination With Chemotherapy
- Rituximab Maintenance Therapy
- Radioimmunotherapies in Combination With Rituximab
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the biological basis for using monoclonal antibodies (MoAbs) and chemoimmunotherapy Describe the management of monoclonal antibody-induced side effects Identify current and experimental therapeutic options for the treatment of B-CLL
|
Downloadable PowerPoint Slides
Speakers' slides from the live symposium
These slide presentations are in Microsoft PowerPoint format. To view the slides in your browser, simply click the 'Download Slides' button. Mac Users: Slides will be downloaded to, and can be accessed from your desktop. You must be logged into the clinicaloptions.com site to view or save the slides.
Recent Developments in the Identification of Biologic Markers and Prognostic Factors in CLL
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 2.10 MB
|
Undetectable Minimal Residual Disease: An Attainable Goal in CLL Treatment
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 2.78 MB
|
Immunotherapy and Chemoimmunotherapy in the Treatment of CLL
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.19 MB
|
Consolidation Strategies With Monoclonal Antibodies in the Treatment of CLL
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 534 KB
|
Treatment of B-Cell Malignancies: Current Standard of Care
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.79 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|